## Gene Summary
CBL (Casitas B-lineage Lymphoma) is a gene that encodes an E3 ubiquitin-protein ligase, which functions in the regulation of signal transduction pathways. CBL proteins are key regulators of signaling cascades and play a crucial role in cell growth, differentiation, and survival by mediating the ubiquitination and subsequent degradation of tyrosine kinases. Located on chromosome 11q23.3, CBL is expressed in various tissues, notably in those of the immune system. The protein encoded by CBL is involved in the negative regulation of many signaling pathways that are initiated by receptor tyrosine kinases, including receptors for epidermal growth factor (EGF), platelet-derived growth factor (PDGF), and others.

## Gene Drugs, Diseases, Phenotypes, and Pathways
CBL mutations and malfunctions have been linked with a range of diseases, primarily cancers such as myeloid disorders and lymphomas. The gene's role in ubiquitination makes it a pivotal player in the degradation of proteins that if otherwise unregulated, can lead to oncogenic transformations. CBL is involved in several critical cellular pathways, including the RAS signal transduction pathway and the PI3K-AKT signaling pathway, both of which are crucial for cellular proliferation and survival. Phenotypically, alterations in CBL function can lead to developmental abnormalities and increased susceptibility to cancers.

## Pharmacogenetics
The pharmacogenetics of CBL primarily involves its role in cancer biology, especially in response to tyrosine kinase inhibitors (TKIs). Mutations in CBL may influence the efficacy and toxicity of these drugs. In leukemia, for instance, alterations in the CBL gene have been associated with modified responses to treatments like imatinib, a drug used predominantly for treating chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GISTs). The differential response is likely due to CBLâ€™s role in the degradation of BCR-ABL, the oncogene targeted by imatinib. More broadly, understanding the ubiquitin-proteasome system, in which CBL functions, can guide the use of proteasome inhibitors in various malignancies, highlighting the need for pharmacogenetic considerations in cancer therapy involving these pathways.